Lv11
20 积分 2026-04-03 加入
Cardiovascular outcomes of GLP-1RA vs SGLT2i in MASLD and type 2 diabetes: real-world evidence
2小时前
已完结
Combination therapies for metabolic dysfunction-associated steatohepatitis: challenges and opportunities
2小时前
已完结
The effect of lipid-lowering treatment on indices of MASLD in familial hypercholesterolemia patients
4小时前
已完结
Association of chronic kidney disease and type 2 diabetes mellitus with metabolic dysfunction-associated steatotic liver disease and liver fibrosis assessed by transient elastography: a cross-sectional study based on NHANES 2017–2020
1个月前
已完结
Longitudinal Changes in Fibrosis Markers: Monitoring Stiffness/Fibrosis Progression and Prognostic Outcomes in MASLD
1个月前
已完结
Safety and efficacy of once-weekly efruxifermin versus placebo in metabolic dysfunction-associated steatohepatitis (HARMONY): 96-week results from a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial
1个月前
已完结
Head-to-head comparison of MASH resolution index versus FAST for noninvasive prediction of resolution of MASH on biopsy
1个月前
已完结
Finerenone in Type 1 Diabetes and Chronic Kidney Disease
1个月前
已完结
皖公网安备34019202002308
